ホーム>>Signaling Pathways>> Stem Cell>> Wnt/β-catenin>>SKI II

SKI II (Synonyms: SKI II, SPHK I2)

カタログ番号GC16701

SKI-IIは、スフィンゴシンキナーゼ(SK)活性の経口活性および合成阻害剤であり、IC50値は、SK1およびSK2についてそれぞれ78μMおよび45μMである。 SKI II は、そのリソソームおよび/またはプロテアソーム分解を誘導することにより、SK1 の不可逆的な阻害を引き起こします。

Products are for research use only. Not for human use. We do not sell to patients.

SKI II 化学構造

Cas No.: 312636-16-1

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$41.00
在庫あり
25mg
$70.00
在庫あり
100mg
$253.00
在庫あり
500mg
$1,112.00
在庫あり
1g
$1,916.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SKI II is an inhibitor of sphingosine kinase with IC50 value of 0.5μM[1].

SKI II is selective against SK and has no inhibition of human protein kinases ERK2, PKC-I and the lipid kinase PI3K. It is reported that SKI II is not a competitive inhibitor at the ATP-binding site of SK. SKI II also inhibits endogenous SK in intact MDA-MB-231 cells [1].

As a SK inhibitor, SKI II prevents SK from catalyzing the generation of sphingosine 1-phosphate (S1P). The blockage of S1P formation leads to inhibition of proliferation, as well as the induction of apoptosis in cancer cells. SKI II shows cytotoxicity in T-24 human bladder carcinoma cells, MCF-7 human breast adenocarcinoma cells and the subline of MCF-7 cells, MCF-7/VP, with IC50 values of 4.6μM, 1.2μM and 0.9μM, respectively [1].

References:
[1] French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.

レビュー

Review for SKI II

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SKI II

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.